Probiotics and fecal bacteriotherapy: the line between deception and treatment
References
Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017; 9(9): pii: E1021.
Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A con-sumer’s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis 2017; 49(11): 1177–84.
Scourboutakos MJ, Franco-Arellano B, Murphy SA, Norsen S, Comelli EM, L’Abbé MR. Mismatch between Probiotic Bene-fits in Trials versus Food Products. Nutrients 2017; 9(4): pii: E400.
Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44(5): 854–9.
Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastro-enterol 2012; 107(11): 1755; author reply p.17551−6.
Wagner RD, Johnson SJ. Probiotic bacteria prevent Salmonella - induced suppression of lymphoproliferation in mice by an im-munomodulatory mechanism. BMC Microbiol 2017; 17(1): 77.
Borrelli L, Aceto S, Agnisola C, De Paolo S, Dipineto L, Stilling RM, et al. Probiotic modulation of the microbiota-gut-brain axis and behaviour in zebrafish. Sci Rep 2016; 6: 30046.
Ait-Belgnaoui A, Colom A, Braniste V, Ramalho L, Marrot A, Cartier C, et al. Probiotic gut effect prevents the chronic psy-chological stress-induced brain activity abnormality in mice. Neurogastroenterol Motil 2014; 26(4): 510–20.
Crumeyrolle-Arias M, Jaglin M, Bruneau A, Vancassel S, Cardona A, Daugé V, et al. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. Psychoneuroendocrinology 2014; 42: 207–17.
Nishino R, Mikami K, Takahashi H, Tomonaga S, Furuse M, Hiramoto T, et al. Commensal microbiota modulate murine behaviors in a strictly contamination-free environment con-firmed by culture-based methods. Neurogastroenterol Motil 2013; 25(6): 521–8.
Luk B, Veeraragavan S, Engevik M, Balderas M, Major A, Runge J, et al. Postnatal colonization with human “infant-type” Bifidobacterium species alters behavior of adult gnotobiotic mice. PloS One 2018; 13(5): e0196510.
Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979; 23(2): 403–11.
Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, et al. In vitro selection criteria for probiotic bac-teria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001; 73(2 Suppl): 386S−92S.
Smirnov KS, Maier TV, Walker A, Heinzmann SS, Forcisi S, Martinez I, et al. Challenges of metabolomics in human gut microbiota research. Int J Med Microbiol 2016; 306(5): 266−79.
Vernocchi P, Del Chierico F, Putignani L. Gut Microbiota Profil-ing: Metabolomics Based Approach to Unravel Compounds Affecting Human Health. Front Microbiol 2016; 7: 1144.
Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 2016; 14(1): 20–32.
Mikov M. The metabolism of drugs by the gut flora. Eur J Drug Metab Pharmacokinet 1994; 19(3): 201–7.
Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10(2): 88–103.
Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. Sci Rep 2017; 7(1): 12115.
Bojic G, Golocorbin-Kohn S, Stojancevic M, Mikov M, Suvajdzic L. Metabolic activity of gut microbiota and xenobiotics. Matica Srpska J Nat Sci 2015; (128): 47–55.
Gong D, Yu X, Wang L, Kong L, Gong X, Dong Q. Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn’s Disease via Modulation of the Gut Microbiota. Biomed Res Int 2017; 2017: 8102589.
Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, et al. Distinct gut microbiota profiles in patients with pri-mary sclerosing cholangitis and ulcerative colitis. World J Gas-troenterol 2017; 23(25): 4548–58.
Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Thera-py. Front Microbiol 2019; 10:1136.
Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int 2017; 66(4): 515–22.
Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the In-fant Gut Microbiota. Microbiol Mol Biol Rev 2017; 81(4): pii: e00036-17.
Soto A, Martín V, Jiménez E, Mader I, Rodríguez JM, Fernández L. Lactobacilli and Bifidobacteria in Human Breast Milk: In-fluence of Antibiotherapy and Other Host and Clinical Fac-tors. J Pediatr Gastroenterol Nutr 2014; 59(1): 78–88.
Rinne M, Kalliomäki M, Salminen S, Isolauri E. Probiotic inter-vention in the first months of life: short-term effects on gas-trointestinal symptoms and long-term effects on gut microbio-ta. J Pediatr Gastroenterol Nutr 2006; 43(2): 200–5.
Fijan S. Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature. Int J Environ Res Public Health 2014; 11(5): 4745–67.
Fredua-Agyeman M, Gaisford S. Comparative survival of com-mercial probiotic formulations: tests in biorelevant gastric flu-ids and real-time measurements using microcalorimetry. Benef Microbes 2015; 6(1): 141–51.
Vecchione A, Celandroni F, Mazzantini D, Senesi S, Lupetti A, Ghelardi E. Compositional Quality and Potential Gastrointes-tinal Behavior of Probiotic Products Commercialized in Italy. Front Med (Lausanne) 2018; 5: 59.
Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, et al. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. J Clin Gastroen-terol 2019; 53(3): e117–25.
Oh B, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, et al. The Ef-fect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. Helicobac-ter 2016; 21(3): 165–74.
Haghdoost M, Taghizadeh S, Montazer M, Poorshahverdi P, Ramouz A, Fakour S. Double strain probiotic effect on Helicobacter pylori infection treatment: A double-blinded randomized con-trolled trial. Caspian J Intern Med 2017; 8(3): 165–71.
Ljungquist O, Kampmann C, Resman F, Riesbeck K, Tham J. Pro-biotics for intestinal decolonization of ESBL-producing En-terobacteriaceae: a randomized, placebo-controlled clinical trial. Clin Microbiol Infect 2019 Sep 5. pii: S1198-743X(19)30481-1. doi: 10.1016/j.cmi.2019.08.019.
Szajewska H. What are the indications for using probiotics in children? Arch Dis 2016; 101(4): 398–403.
Dickson I. Probiotics fail to improve preschool gastroenteritis. Nat Rev Gastroenterol Hepatol 2019; 16(2): 76.
Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: A review. Biomed Pharma-cother 2019; 111: 537–47.
Stefanatou E, Kompoti M, Paridou A, Koutsodimitropoulos I, Gian-nopoulou P, Markou N, et al. Probiotic sepsis due to Saccharo-myces fungaemia in a critically ill burn patient. Mycoses 2011; 54(5): e643–6.
Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, et al. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses 2017; 60(6): 375–80.
Celiberto LS, Pinto RA, Rossi EA, Vallance BA, Cavallini DC. Isolation and Characterization of Potentially Probiotic Bacte-rial Strains from Mice: Proof of Concept for Personalized Probiotics. Nutrients 2018; 10(11): pii: E1684.
Kort R. Personalized therapy with probiotics from the host by TripleA. Trends Biotechnol 2014; 32(6): 291–3.
Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, et al. Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial. PloS One 2017; 12(2): e0171308.
Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Sa-tokari R, et al. European consensus conference on faecal mi-crobiota transplantation in clinical practice. Gut 2017; 66(4): 569–80.
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Ef-fect of Oral Capsule- vs Colonoscopy-Delivered Fecal Micro-biota Transplantation on Recurrent Clostridium difficile In-fection: A Randomized Clinical Trial. JAMA 2017; 318(20): 1985–93.
Cohen NA, Maharshak N. Novel Indications for Fecal Micro-bial Transplantation: Update and Review of the Literature. Dig Dis Sci 2017; 62(5): 1131–45.
Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, et al. The kinetics of gut microbial community composi-tion in patients with irritable bowel syndrome following fecal microbiota transplantation. PloS One 2018; 13(11): e0194904.
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bar-telsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with meta-bolic syndrome. Gastroenterology 2012; 143(4): 913−16.e7.
Kao D, Roach B, Park H, Hotte N, Madsen K, Bain V, et al. Fe-cal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 2016; 63(1): 339–40.
Ren YD, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, et al. Fe-cal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology 2017; 65(5): 1765–8.
Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017; 5(1): 10.
Zhou Y, Xu H, Huang H, Li Y, Chen H, He J, et al. Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? Biomed Res Int 2019; 2019: 3469754.
Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Cur-ry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gas-troenterol 2013; 108(4): 478–98; quiz 499.
Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. System-atic Review: Adverse Events of Fecal Microbiota Transplanta-tion. PloS One 2016; 11(8): e0161174.
Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal Microbiota Transplant for Treatment of Clostridi-um difficile Infection in Immunocompromised Patients. Am J Gastroenterol 2014; 109(7): 1065–71.
Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recur-rent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2016; 315(2): 142–9.
Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Lev-in J, et al. Oral, frozen fecal microbiota transplant (FMT) cap-sules for recurrent Clostridium difficile infection. BMC Med 2016; 14(1): 134.
Arbel LT, Hsu E, McNally K. Cost-Effectiveness of Fecal Mi-crobiota Transplantation in the Treatment of Recurrent Clos-tridium Difficile Infection: A Literature Review. Cureus 2017; 9(8): e1599.
Varier RU, Biltaji E, Smith KJ, Roberts MS, Kyle Jensen M, LaFleur J, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2015; 36(4): 438–44.
Center for Biologics Evaluation and Research (FDA). Im-portant Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms. 2019. Available from: http://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use
Xu M, Xu X, Li J, Li F. Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Me-ta-analysis. Front Psychiatry 2019; 10:473.